Implementing Transmucosal Buprenorphine for Treatment of Opioid Use Disorder: Joint Letter from NYS OASAS and NYS DOH (2/21/19)

https://www.health.ny.gov/diseases/aids/consumers/prevention/buprenorphine/docs/bupe_best_practices_comm_letter_2019.pdf